Over the last few years, the global pharmaceutical industry has undergone significant changes. In recent years, the cost of drugs has been increasing rapidly, a majority of which is contributed by funds allocated to research and development. According to a report published by Congressional Budget Office (CBO) in April 2021, titled, ‘Research and Development in the Pharmaceutical Industry,’ the U.S. pharmaceutical industry’s R&D expenditure in 2019 was nearly $83 billion, spanning a range of activities such as drug discovery, conducting clinical tests, and drug innovation, among others. Additionally, the report also states that the budget share allocated by pharmaceutical companies toward research and development has also increased. The following table shows a rough estimate of the annual R&D expenditure of pharmaceutical companies.

Molecular diagnostics encompasses a rapidly evolving range of assays and systems that facilitate pathogen detection, viral load estimation, antibiotic and antiviral therapy selection, diagnosis of cancer, and other diseases, by the detection and analysis of proteins and nucleic acid sequences. Molecular diagnostics also offer prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy. Molecular diagnostics has evolved to be an integrative aspect of healthcare routines by providing most laboratory tests in infectious disease and genetics, and a continuously increasing number of tests in oncology. The massively parallel methods that have now transcended molecular diagnostics allow sequencing of entire genomes at very low costs. The sequenced databases within and between species provide the information necessary for the development of sensitive and specific diagnostic assays. The effect of extensive sequencing procedures has led to most microorganisms today being classified on the basis of sequence rather than phenotype. A presumptive diagnosis is made if a microbial sequence is present where it should not be.

The research provides an overview of all the M&As and divestitures in the medtech industry during the study period. The M&As focus on three primary areas: The clinical specialty areas where the M&As occur. The purpose behind these deals. oThe impact of the consolidated landscape on healthcare providers, payers, patients, and other market players.

The research study titled ‘Global Medical Grade Tubing Market’ is aimed at assessing the market potential of various applications in the overall medical grade tubing market. The research report constitutes an in-depth study of the global medical grade tubing market, including a thorough analysis of revenues generated by companies involved in the development of medical grade tubing.  Based on the product launches, approvals, and ongoing strategic collaborations, as well as business expansion, the market size and potential for the forecast period 2021-2030 have been estimated. The report focuses on the assessment of the market by product, material, application, end market, and region.

Peptides are a selective, efficacious, and unique class of molecules that bind to specific cell surface receptors, triggering intracellular effects. They are short chains of amino acids linked by a peptide bond. Although they are molecularly poised between small molecules and proteins, peptides have distinctive therapeutic and biochemical properties. They represent an attractive first step in developing novel therapeutics across different areas, including oncology, metabolic, cardiovascular, infectious, endocrine, neurology, and other disorders. For decades, researchers have endeavored to comprehend intracellular protein-protein interactions (PPIs) as they play a critical role in the pathogenesis of numerous disease states. The development of constrained peptides exhibits an emerging approach that addresses challenging PPIs.

The study defines cancer microbiome as the aggregate of microorganisms living in or on the human body along with their genomes that are influencing cancer manifestation and progression. Cancer microbiome sequencing has increasingly become an area of interest for the research community, which has the potential to revolutionize cancer care, largely due to studies that have significantly correlated the microbiome’s involvement in cancer manifestation. This study aims at deciphering the potential of the cancer microbiome sequencing and its larger role in bolstering the current era of precision medicine.

The prevalence of several chronic diseases worldwide and the launch of sophisticated technologies and treatments have contributed to a rapid increase in healthcare expenses. Additionally, patients nowadays expect high-quality care at an affordable cost. Thus, it has become imperative for players in the healthcare industry to reduce the cost of their healthcare services while providing high-quality care to patients. Efficient healthcare logistics services provide a remarkable opportunity for controlling healthcare costs through the implementation of best practices.

Immunotherapy, a non-traditional treatment, has become a prominent approach for treating many diseases, especially cancer, because it provides superior efficacy and safety. During this era of precision medicine and effective immunotherapies, the necessity for rapid and efficient antineoplastic development has never been greater. Biologics or biologic drugs are derived from living organisms and have proved to be a cure for several chronic conditions that were previously considered untreatable.

AI in healthcare has enormous and far-reaching potential, from mobile training solutions to drug discovery, which fall within the realm of machine learning. Artificial intelligence (AI) in healthcare refers to the use of complex algorithms that are supposed to perform certain tasks automatically. When researchers, doctors, and scientists input data into computers, newly developed algorithms can review, interpret, and even suggest solutions to complex medical problems.

全球疫情有明显抬头趋势，国内动态清零政策短期内不会变化。进入2022年3月以来，全球确诊人数增速有明显抬头趋势，Omicron仍然为主要流行株。国内各地散点疫情也呈爆发状态，截至3月15日，国内单日新增确诊病例1860人，为武汉疫情以来国内疫情形势最严峻的一次。从政策上看，国内防疫政策总基调不变，坚持“外防输入、内防反弹”总策略、“动态清零”总方针。监测模式变为推进“抗原筛查、核酸诊断” ，在核酸检测基础上增加抗原检测作为补充。